KNS
Kiniksa Pharma
Stock
Stock
ISIN: GB00BRXB0C07
Ticker: KNSA
GB00BRXB0C07
KNSA
Price
Price
CHART BY
Frequently asked questions
What is Kiniksa Pharma's market capitalization?
The market capitalization of Kiniksa Pharma is $6.15B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is Kiniksa Pharma's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for Kiniksa Pharma is 80.16. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for Kiniksa Pharma?
Kiniksa Pharma's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $0.984. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Kiniksa Pharma's stock?
Currently, 8 analysts cover Kiniksa Pharma's stock, with a consensus target price of $98.00. Analyst ratings provide insights into the stock's expected performance.
What is Kiniksa Pharma's revenue over the trailing twelve months?
Over the trailing twelve months, Kiniksa Pharma reported a revenue of $840.85M.
What is the EBITDA for Kiniksa Pharma?
Kiniksa Pharma's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $102.04M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Kiniksa Pharma?
Kiniksa Pharma has a free cash flow of $182.84M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Kiniksa Pharma have, and what sector and industry does it belong to?
Kiniksa Pharma employs approximately 366 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Kiniksa Pharma's shares?
The free float of Kiniksa Pharma is 45.02M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $6.15B
- EPS (TTM)
- $0.984
- Free Float
- 45.02M
- P/E ratio (TTM)
- 80.16
- Revenue (TTM)
- $840.85M
- EBITDA (TTM)
- $102.04M
- Free Cashflow (TTM)
- $182.84M
Pricing
- 52W span
- $35.51$82.97
Analyst Ratings
The price target is $98.00 and the stock is covered by 8 analysts.
Buy
8
Hold
0
Sell
0
Information
Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.
- Employees
- 366
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- GB00BRXB0C07
- Primary Ticker
- KNSA
Fundamentals & EOD data from FactSet